This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2012 Nov;9(11):610.

doi: 10.1038/nrclinonc.2012.165. Epub 2012 Sep 11.

Gastrointestinal cancer: New drug shows promise in refractory colorectal cancer

PMID: 22965155
DOI: 10.1038/nrclinonc.2012.165

Comment

Gastrointestinal cancer: New drug shows promise in refractory colorectal cancer

Rebecca Kirk. Nat Rev Clin Oncol. 2012 Nov.

. 2012 Nov;9(11):610.

doi: 10.1038/nrclinonc.2012.165. Epub 2012 Sep 11.

Author

PMID: 22965155
DOI: 10.1038/nrclinonc.2012.165

No abstract available

PubMed Disclaimer

Comment on

TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial.
Yoshino T, Mizunuma N, Yamazaki K, Nishina T, Komatsu Y, Baba H, Tsuji A, Yamaguchi K, Muro K, Sugimoto N, Tsuji Y, Moriwaki T, Esaki T, Hamada C, Tanase T, Ohtsu A. Yoshino T, et al. Lancet Oncol. 2012 Oct;13(10):993-1001. doi: 10.1016/S1470-2045(12)70345-5. Epub 2012 Aug 28. Lancet Oncol. 2012. PMID: 22951287 Clinical Trial.

References

1. Lancet Oncol. 2012 Oct;13(10):993-1001 - PubMed

Publication types

Actions

LinkOut - more resources

Full Text Sources
- Nature Publishing Group
- Ovid Technologies, Inc.